TIL Therapy for Melanoma: What the First Approved 'Tumour Cell' Treatment Shows

CAR-T therapy gets most of the attention, but in 2024 a different kind of cell therapy quietly made history: the first one ever approved for a solid tumour. It's called lifileucel, and it works on a beautifully simple idea — your immune system has already sent cells into the tumour to fight it, so why not collect those cells, grow a huge army of them, and give them back? A 5-year analysis published in 2025 lets us judge how well it actually works ¹. The answer is genuinely encouraging, and worth reading honestly — because it's also intensive treatment.

For a field that has struggled for decades to turn the immune system against solid cancers, this is a real milestone.

What question did the researchers ask?

The study asked how well, and how durably, lifileucel works in people with advanced melanoma whose cancer had already stopped responding to standard immunotherapy (PD-1 checkpoint inhibitors) — a group with few good options left ¹.

Lifileucel is a TIL therapy — short for tumour-infiltrating lymphocytes. The concept: surgeons remove a piece of the patient's tumour, technicians find the immune cells (T cells) that had naturally infiltrated it, and grow them into billions of cells in the lab. The patient then has chemotherapy to "make room", receives the expanded cells back in a single infusion, and is given interleukin-2 to help the cells work. Unlike CAR-T, the cells aren't genetically engineered — they're the patient's own anti-tumour cells, just vastly multiplied.

What did the trial find?

In the C-144-01 trial, about 31% of patients responded to lifileucel — meaning roughly one in three saw their melanoma shrink — including a small group whose tumours essentially disappeared ¹. That may not sound dramatic until you remember the context: these were patients whose cancer had already beaten the best available immunotherapy, where further responses are hard to come by.

The more striking finding was durability. Among those who responded, the benefit often lasted a remarkably long time — a median duration of response measured in years, with a meaningful fraction still responding at the 5-year mark ¹. In advanced melanoma, long-lasting responses like that are exactly what matters, and they're why this therapy earned approval.

How strong is this evidence?

This is solid evidence — strong enough to earn FDA approval — but it's important to read it for what it is. A roughly 31% response rate means most patients did not respond, and the treatment is demanding: the chemotherapy and high-dose interleukin-2 carry real side effects, and the whole process requires an experienced centre. It is approved specifically for advanced melanoma after other treatments have failed, not as a first option or for other cancers (though TIL therapy is being studied elsewhere).

So the honest framing is: a genuine breakthrough — the proof that cell therapy can work against a solid tumour — that is also intensive and partial. For the right patient, a one-in-three chance of a durable response after everything else has failed is hugely valuable. For others, it may not be the right path.

What could this mean if you are considering treatment?

Lifileucel is an approved, real treatment — a meaningful distinction from most of the experimental therapies we cover. But it's delivered at specialist cancer centres equipped to manage the chemotherapy, cell infusion and interleukin-2, and it's specifically for advanced melanoma after immunotherapy. The useful questions for an oncology team: Am I a candidate based on my cancer type and prior treatments? What does the process and recovery involve? What are the realistic odds and risks for me? Beware anyone marketing "TIL therapy" or "tumour cell therapy" outside this established, specialist context.

What we see at the clinic

Cancer patients sometimes ask us about the wave of "cell therapies" they've read about. We think lifileucel is genuinely encouraging news — a real, approved demonstration that immune-cell therapy can work against solid tumours, which has been one of oncology's hardest goals. Our role is to help people understand that this is intensive, specialist hospital care with real trade-offs, delivered through proper cancer centres — not something to seek from a wellness clinic.

Common questions

Is lifileucel a cure for melanoma? No. About 31% of heavily pre-treated patients responded, with often durable benefit ¹ — meaningful, but most patients didn't respond, so it's an important option, not a cure.

How is TIL therapy different from CAR-T? TIL uses the patient's own tumour-fighting cells, simply grown in huge numbers; CAR-T genetically engineers cells to hit a chosen target. TIL was the first cell therapy approved for a solid tumour.

Is it gentle? No. It involves chemotherapy, a cell infusion and high-dose interleukin-2, with real side effects, and needs an experienced centre.

[1] Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. 2025. https://pubmed.ncbi.nlm.nih.gov/40454684/

Key takeaway

Lifileucel made history as the first cell therapy approved for a solid tumour, growing a patient's own tumour-fighting immune cells into billions and giving them back. In advanced melanoma that had defeated standard immunotherapy, about a third of patients responded, often for years — a genuine landmark. It's intensive, specialist treatment that doesn't work for everyone, but for the right patient it's a real and valuable option.